Results for the year ended 30 June 2013

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

          Preliminary audited results for the year ended 30 June 2013          

Bioventix plc (ISDX: BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces its final results for the year ended 30 June
2013.

Highlights:

  * Revenues have grown by 14% compared with the year to 30 June 2012
   
  * Profit after tax increased by 23% compared with the year to 30 June 2012
   
  * Cash balances of GBP2.585m at 30 June 2013 (GBP2.179m at 30 June 2012)
   
  * Dividend declared of 8.77p (2012: 7.26p)
   
CHAIRMAN AND CHIEF EXECUTIVE'S STATEMENT

FOR THE YEAR ENDED 30 JUNE 2013

We are pleased to report the results for the financial year ended 30 June 2013.
Revenues for the year of £2.706m (2012:£2.383m) were 14% up on the previous
year. With the costs broadly similar to previous years, profits have increased
by a greater percentage (23%).

The core historic business has remained strong and has been supplemented by
growth in other areas. We have reported consistently on our positive outlook
for our vitamin D activities and a leading antibody called vitD3.5H10. Revenue
from this product has continued to grow and increasing royalties are now being
generated as customer products (assays for vitamin D deficiency) reach markets
around the world. Bioventix now has eleven licensees for vitD3.5H10 ranging
from large to small diagnostics companies. We expect more licenses to be
concluded over the next year and remain optimistic that revenues from
vitD3.5H10 will continue to grow over the next couple of years as more
vitD3.5H10-based products reach the market. Many customers prefer to keep the
identity of their suppliers confidential and we naturally respect this.
However, some information inevitably becomes available through public access
mechanisms such as the US Food and Drug Administration 510k approval process.
The term "sheep monoclonal antibody" is indicative of a Bioventix antibody and
this is evident in the apllications of Ortho Clinical Diagnostics and Tosoh.

Our on-going pipeline development has resulted in new antibodies to
androstenedione (an androgenic steroid similar to testosterone) and TSH
(thyroid stimulating hormone) being supplied to customers in the form of
evaluation samples. Antibodies to T4 (thyroxine) will be released later in
2013.

We are also cautiously optimistic about growth prospects in China. There are
rapidly emerging Chinese customers and this represents a growth opportunity. It
is noteworthy that in the financial year, around 10% of Bioventix shipments
(including samples) were destined for China. The actual revenues are less than
10% of the total but the volume of shipments is encouraging for future growth.

Another route to pipeline development comes from sponsored antibody creation
projects whereby customers pay for antibody creation in return for exclusive
use of the antibodies created. We have three such projects on-going at present,
one of which is in bone metabolism.

These additional products could deliver additional growth later in the decade
though their collective impact is likely to be less than vitamin D.

Cash balances at 30 June 2013 of £2.585m (2012: £2.179m) were significantly
higher than the previous year despite significantly increased dividend
payments.

The Board remains confident that the Company will continue the progress it has
made over the last few years and is pleased to declare an increased second
interim dividend of 8.7p per Ordinary Share (2012: 7.26p) continuing the
progressive dividend policy adopted since 2010. The shares will be marked
ex-dividend on 2 October 2013 and the dividend will be paid on 14 October 2013
to shareholders on the register at close of business on 4 October 2013.

During December 2012, funds under the Miton portfolio acquired 22.7% of
Bioventix plc, stock which was previously held by SpringHill Bioventures.
SpringHill have continued their planned sale of Bioventix shares and no longer
hold any Bioventix stock. We now have a number of new and high calibre
shareholders such as Henderson Global Investors and ISIS Equity Partners. We
would like to thank SpringHill for their support over the past ten years and
warmly welcome all our new shareholders.

The continued excellent performance of the company in a globally competitive
market for antibodies is very satisfying. Our sheep monoclonal antibody
technology continually delivers performance antibodies to our customers.
However, the operation of the antibody technology is made possible by the
efforts of our expert staff and we would like to thank them for their
remarkable achievements over the last year.

For further information please contact:

Bioventix plc           Chief Executive        Tel: [phone]    
                        Officer                                      
Peter Harrison                                                       
                                                                     
finnCap Ltd             Corporate Finance      Tel: [phone]    
                                                                     
Geoff Nash/Simon Hicks  Corporate Broking                            
                                                                     
Tom Jenkins                                                          

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares (BVXP)
were admitted to trading on PLUS-SX in April 2010.


PROFIT AND LOSS ACCOUNT

FOR THE YEAR ENDED 30 JUNE 2013

                                                             2013          2012
                                                                               
                                                                £             £
                                                                               
TURNOVER                                                2,706,436     2,383,971
                                                                               
Cost of sales                                           (188,328)     (203,579)
                                                                               
GROSS PROFIT                                            2,518,108     2,180,392
                                                                               
Administrative expenses                                 (708,697)     (685,541)
                                                                               
OPERATING PROFIT                                        1,809,411     1,494,851
                                                                               
Interest receivable and similar income                     12,043        11,536
                                                                               
Interest payable and similar charges                         (97)         (120)
                                                                               
PROFIT ON ORDINARY ACTIVITIES BEFORE                    1,821,357     1,506,267
TAXATION                                                                       
                                                                               
Tax on profit on ordinary activities                    (299,903)     (269,069)
                                                                               
PROFIT FOR THE FINANCIAL YEAR                           1,521,454     1,237,198
                                                                               
EARNINGS PER SHARE                                                             
                                                                               
Basic                                                      30.28p        24.62p
                                                                               
Diluted                                                    30.28p        24.62p



All amounts relate to continuing operations.


There were no recognised gains and losses for 2013 or 2012 other than those
included in the Profit and loss account.

BALANCE SHEET

AS AT 30 JUNE 2013

                                                     2013                  2012
                                                                               
                                             £          £          £          £
                                                                               
FIXED ASSETS                                                                   
                                                                               
Intangible assets                                  10,000                30,000
                                                                               
Tangible assets                                   438,766               442,223
                                                                               
                                                  448,766               472,223
                                                                               
CURRENT ASSETS                                                                 
                                                                               
Stocks                                 148,530                85,687           
                                                                               
Debtors                              1,329,362               816,182           
                                                                               
Cash at bank and in hand             2,585,506             2,179,138           
                                                                               
                                     4,063,398             3,081,007           
                                                                               
CREDITORS:                           (299,737)             (206,828)           
                                                                               
amounts falling due within one                                                 
year                                                                           
                                                                               
NET CURRENT ASSETS                              3,763,661             2,874,179
                                                                               
TOTAL ASSETS LESS CURRENT LIABILITIES           4,212,427             3,346,402
                                                                               
PROVISIONS FOR LIABILITIES                                                     
                                                                               
Deferred Tax                                      (7,602)               (6,716)
                                                                               
NET ASSETS                                      4,204,825             3,339,686
                                                                               
CAPITAL AND RESERVES                                                           
                                                                               
Called up share capital                           251,269               251,269
                                                                               
Capital redemption reserve                          1,231                 1,231
                                                                               
Profit and loss account                         3,952,325             3,087,186
                                                                               
SHAREHOLDERS' FUNDS                             4,204,825             3,339,686

CASH FLOW STATEMENT

FOR THE YEAR ENDED 30 JUNE 2013

                                                             2013          2012
                                                                               
                                                                £             £
                                                                               
Net cash flow from operating activities                 1,341,108     1,469,254
                                                                               
Returns on investments and servicing of                    11,946        11,416
finance                                                                        
                                                                               
Taxation                                                (269,040)     (241,572)
                                                                               
Capital expenditure and financial investment             (21,331)      (16,700)
                                                                               
Equity dividends paid                                   (656,315)     (574,904)
                                                                               
INCREASE IN CASH IN THE YEAR                              406,368       647,494

RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS/DEBT

FOR THE YEAR ENDED 30 JUNE 2013

                                                             2013          2012
                                                                               
                                                                £             £
                                                                               
Increase in cash in the year                              406,368       647,494
                                                                               
MOVEMENT IN NET DEBT IN THE YEAR                          406,368       647,494
                                                                               
Net funds at 1 July 2012                                2,179,138     1,531,644
                                                                               
NET FUNDS AT 30 JUNE 2013                               2,585,506     2,179,138

TURNOVER

The whole of the turnover is attributable to the development and supply of
antibodies.

The geographical split of turnover is:

                                                             2013          2012
                                                                               
                                                                £             £
                                                                               
United Kingdom                                             95,895        80,320
                                                                               
Other EU                                                1,309,774     1,235,105
                                                                               
USA                                                     1,020,956       964,851
                                                                               
Rest of the World                                         279,811       103,695
                                                                               
Total                                                   2,706,436     2,383,971